A PATIENT WITH CHRONIC HEPATITIS-C WHO SIMULTANEOUSLY DEVELOPED INTERSTITIAL PNEUMONIA, HEMOLYTIC-ANEMIA AND CHOLESTATIC LIVER DYSFUNCTION AFTER ALPHA-INTERFERON ADMINISTRATION

被引：27
作者：
HIZAWA, N
KOJIMA, J
KOJIMA, T
SUKOH, N
YAMAGUCHI, E
KAWAKAMI, Y
MATSUSHIMA, T
机构：
[1] Department of Medicine, School of Medicine, Hokkaido University, Sapporo 060
来源：
INTERNAL MEDICINE | 1994年 / 33卷 / 06期
关键词：
SIDE EFFECTS; LYMPHOCYTE STIMULATION TEST; SHO-SAIKO-TO;
D O I：
10.2169/internalmedicine.33.337
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Following a three-week administration of alpha-interferon (IFN-alpha), a 62-year-old woman with chronic hepatitis C manifested fever and dyspnea and showed diffuse infiltrative opacities on chest roentgenograms. Her laboratory data included results of anemia with reticulocytosis, a decreased complement level and hepatitis with elevated ALP, LDH and gamma-GTP. Because laboratory data also revealed a positive lymphocyte stimulation test for IFN-alpha, this cytokine was considered to be responsible for the development of interstitial pneumonia. hemolytic anemia and cholestatic liver dysfunction due to its immunomodulatory effects. Although these three disorders have been reported to develop singly after IFN-alpha therapy, this is the first report of a patient in whom these disorders occurred simultaneously.
引用
收藏
页码：337 / 341
页数：5
相关论文
共 17 条
  • [1] Davis G.L., Balart L.A., Schiff E.R., Et al., Treatment of chronic hepatitis C with recombinant interferon alfa, N Engl J Med, 321, (1989)
  • [2] Onoda K., Takai K., Sanada M., Sadao A., Watanabe T., Autoimmune hemolytic anemia induced by IFN-α therapy in a case of IgG-K type multiple myeloma, Jpn J Clin Hematol, 33, (1992)
  • [3] Schilling P.J., Kurzrock R., Kantarjian H., Gutterman J.U., Talpaz M., Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia, Cancer, 68, (1991)
  • [4] Schattner A., Review: Interferons and autoimmunity, Am J Med Sci, 295, (1988)
  • [5] Peters M., Mechanism of action of interferon, Semin Liv Dis, 9, (1989)
  • [6] Quesada J.R., Talpaz M., Rios A., Kurzrock R., Gutterman J.U., Clinical toxicity of interferons in cancer patients, J Clin Oncol, 4, (1986)
  • [7] Ronnblom L.E., Alm G.V., Oberg K.E., Autoimmunity after IFN-a therapy for malignant carcinoid tumors, Ann Intern Med, 115, (1991)
  • [8] Akard L.P., Hoffman R., Elias L., Saiers J.H., Alpha-interferon and immune hemolytic anemia, Ann Intern Med, 105, (1986)
  • [9] Hakozaki Y., Shirahama T., Kato M., Et al., A case of chronic hepatitis C with drug-induced cholestatic hepatic disorder during interferon administration, Acta Hepatol Jpn, 33, (1992)
  • [10] McLaughlin P., Talpaz M., Quesada J.R., Et al., Immune thrombocytopenia following α-interferon therapy in patients with cancer, JAMA 254:1353, (1985)
12